Join to View Full Profile
12902 Usf Magnolia DrTampa, FL 33612
Phone+1 813-745-7365
Fax+1 813-449-8618
Dr. Lu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Charles Lu is an oncologist based in Tampa, FL, specializing in thoracic cancer. He earned his medical degree from Yale School of Medicine in 1991 and completed his residency in internal medicine, followed by a fellowship in hematology and medical oncology at Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute by 1997. His recent publications include research on thyroid cancer, lung cancer, and cancer therapy-related immune responses, with his work appearing in prestigious journals such as JAMA Oncology, Nature Medicine, and Journal of Thoracic Oncology.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1994 - 1997- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1991 - 1994
Yale School of MedicineClass of 1991
Certifications & Licensure
FL State Medical License 2021 - 2028
TX State Medical License 1999 - 2025
OK State Medical License 2020 - 2021
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015
Publications & Presentations
PubMed
- Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use.Utsav Joshi, Faustine Ong, Daniel Melzer, Joanna C Ma, Andreas Saltos
Clinical Lung Cancer. 2026-03-01 - 13 citationsReceptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review.Yang Xia, Kaiwen Wang, Jing Zhao, Zhaohui Arter, Yongchang Zhang
Journal of Thoracic Oncology. 2025-04-01 - 39 citationsAnti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial.Maria E Cabanillas, Ramona Dadu, Renata Ferrarotto, Maria Gule-Monroe, Suyu Liu
JAMA Oncology. 2024-12-01
Press Mentions
Tonsil Cancer Survivor Travels from New York to Houston for TreatmentJune 6th, 2022
Stage IV Salivary Gland Cancer Survivor: How Proton Therapy Saved My CareerJanuary 9th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
